XRP Registers Gains Despite Negative Crypto Market Results
After a fairly long period of trading in a relatively narrow range, XRP appears to be defying the mostly negative results of the broader crypto market by registering gains over the past day.
XRP has appreciated by just over 8% in the last 24 hours, reaching around $0.646 at the time of writing, the highest since March 25, fueled by optimism surrounding the potential settlement of the SEC’s lawsuit against Ripple and the planned unlocking of tokens.
Traders are interpreting the recent SEC filing , which hints at an amendment to the complaint against Binance without naming tokens, as a positive sign for the resolution of the case against Ripple.
READ MORE:
XRP Registers Gains Despite Negative Crypto Market ResultsThis spurs bullish sentiment despite Ripple’s planned unlocking of 1 billion XRP.
This market optimism comes despite the logical expectation that an increase in token supply will lead to a drop in prices. However, research suggests that the additional liquidity from unlocking the tokens may actually support the bullish trend.
In contrast to XRP’s performance, the crypto sector’s market cap has lost just over 0.4% in the past 24 hours. Bitcoin ( BTC ) and Ethereum ( ETH ) also registered losses of 0.9% and 0.6% respectively over the same time period.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
AI Sell-off Hits Anthropic IPO, Potential Valuation Expected to Drop to $1.2–1.3 Trillion
The valuation range discussed by potential investors has been lowered from the previous high of $2 trillion to between $1.2 trillion and $1.3 trillion, and some strategists have even suggested going below $1 trillion to ensure safety. In the face of significant market volatility and financial concerns such as quarterly losses, Anthropic is facing tough decisions, including a discounted valuation, reducing the size of the offering, or postponing the listing.
Moderna Q3 revenue up 29% year-on-year, far exceeding expectations, raises full-year revenue growth guidance to 15%-25% | Earnings Report Insight
Moderna's Q3 revenue increased by 29% year-on-year to $1.31 billion, with profits significantly exceeding expectations. The company raised its 2026 revenue growth guidance to 15%-25%. The ramp-up of next-generation COVID-19 and flu vaccines, along with international market expansion, has driven performance improvement. Phase III data for the personalized cancer vaccine has also shown positive progress. The company is simultaneously advancing cost reduction and pipeline R&D, with year-end cash expectations significantly raised.
Eli Lilly (LLY.US) "lowers its stance" and joins forces with former rival Hims (HIMS.US) to compete for the self-pay weight loss drug market
Eli Lilly is collaborating with Hims & Hers Health, leveraging the telehealth company’s large customer base to expand access to its blockbuster weight loss drugs and boost sales of medications, including its new oral weight loss drug Foundayo.
Crypto prices
More
